Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.

Capetti AF, Micale M, Carenzi L, Niero F, Landonio S, Vimercati S, Dedivitiis G, Rizzardini G.

Medicine (Baltimore). 2017 Feb;96(7):e5728. doi: 10.1097/MD.0000000000005728.

2.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.

3.

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.

Namakoola I, Kasamba I, Mayanja BN, Kazooba P, Lutaakome J, Lyagoba F, Kapaata AA, Kaleebu P, Munderi P; CoLTART study team..

BMC Res Notes. 2016 Dec 23;9(1):515. doi: 10.1186/s13104-016-2309-7.

4.

Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.

Di Biagio A, Riccardi N, Taramasso L, Capetti A, Cenderello G, Signori A, Vitiello P, Guerra M, de Socio GV, Cassola G, Quirino T, Viscoli C.

Int J Antimicrob Agents. 2016 Nov;48(5):551-554. doi: 10.1016/j.ijantimicag.2016.07.009.

PMID:
27566908
5.

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.

Gantner P, Bani-Sadr F, Garraffo R, Roger PM, Treger M, Jovelin T, Pugliese P, Rey D; Dat’AIDS cohort..

PLoS One. 2016 Oct 31;11(10):e0164240. doi: 10.1371/journal.pone.0164240.

6.

Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Kelesidis T, Tran TT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS.

Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3093. [Epub ahead of print]

PMID:
27661466
7.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H.

Lancet HIV. 2016 Sep;3(9):e410-20. doi: 10.1016/S2352-3018(16)30016-9.

PMID:
27562742
8.

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.

Ferretti F, Bigoloni A, Passeri L, Galli L, Longo V, Gerevini S, Spagnuolo V, Gisslen M, Zetterberg H, Fuchs D, Cattaneo D, Caramatti G, Lazzarin A, Cinque P, Castagna A.

Medicine (Baltimore). 2016 Jul;95(28):e4144. doi: 10.1097/MD.0000000000004144.

9.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group..

J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103.

PMID:
27068399
10.

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.

Gubavu C, Prazuck T, Niang M, Buret J, Mille C, Guinard J, Avettand-Fènoël V, Hocqueloux L.

J Antimicrob Chemother. 2016 Apr;71(4):1046-50. doi: 10.1093/jac/dkv430.

11.

Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.

Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB.

HIV Med. 2016 May;17(5):358-67. doi: 10.1111/hiv.12348.

PMID:
26709605
12.

Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy.

Kahlert C, Bregenzer A, Gutmann C, Otterbech S, Hoffmann M, Schmid P, Vernazza P.

Infection. 2016 Jun;44(3):329-35. doi: 10.1007/s15010-015-0866-7.

PMID:
26661659
13.

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.

Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ.

Clin Ther. 2015 Sep 1;37(9):1876-93. doi: 10.1016/j.clinthera.2015.07.022. Review.

PMID:
26319088
14.

Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.

Meditz AL, Palmer C, Predhomme J, Searls K, Kerr B, Seifert S, Caraway P, Gardner EM, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):1015-22. doi: 10.1089/AID.2014.0301.

15.

Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population.

Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT.

PLoS One. 2015 Jun 8;10(6):e0129519. doi: 10.1371/journal.pone.0129519.

16.

Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.

Puligujja P, Araínga M, Dash P, Palandri D, Mosley RL, Gorantla S, Poluektova L, McMillan J, Gendelman HE.

Antiviral Res. 2015 Aug;120:85-8. doi: 10.1016/j.antiviral.2015.05.009.

17.

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA.

Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327.

18.

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

Lahiri CD, Tao S, Jiang Y, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava A, Sanford S, Ofotokun I.

AIDS. 2015 Jun 1;29(9):1113-5. doi: 10.1097/QAD.0000000000000659.

19.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group..

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567.

PMID:
25831464
20.

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.

JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.

PMID:
25706092

Supplemental Content

Loading ...
Support Center